Researchers test Long-Term safety of new sickle cell pill
NCT ID NCT04610866
Summary
This study is testing the long-term safety and effects of a drug called mitapivat for adults with stable sickle cell disease. It is an extension for 15 people who benefited from an earlier short-term study. Participants will take the pill twice daily for up to two years while researchers monitor their health, energy levels, and quality of life.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SICKLE CELL DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.